Weight Watchers appoints Heather Thiltgen to board of directors

WW International, Inc. (NASDAQ: WW) announced the appointment of Heather Thiltgen to its board of directors, effective April 20, 2026. Thiltgen currently serves as president of Presbyterian Health Plan and previously held the position of president and CEO of WellSense Health Plan.

Thiltgen brings healthcare leadership experience in areas including expanding coverage and access to GLP-1 therapies, navigating regulatory environments, accelerating growth by rebuilding membership bases, and delivering health outcomes through medical and telehealth solutions.

"We are delighted to welcome Heather, whose successful track record of driving profitable growth across diverse healthcare markets and navigating complex regulatory environments will strengthen the Board's oversight of the Company's long-term strategy," said Gene Davis, chairman of the Weight Watchers board.

The appointment reflects the board's commitment to adding directors with relevant qualifications as Weight Watchers evolves in the healthcare landscape. The company recently appointed Sue Gove and Lisa Gavales to the board.

Thiltgen will serve as director until the company's 2026 annual meeting of shareholders and is expected to stand for election at that meeting. She will serve on the board's Compensation and Benefits Committee. With her appointment, the Weight Watchers board has expanded to six members, all of whom are independent.

At Presbyterian Health Plan, Thiltgen leads an end-to-end turnaround of the health insurance division of Presbyterian Healthcare Services. During her tenure at WellSense Health Plan, she grew revenue, led a multi-year transformation, increased Massachusetts Medicaid market share and expanded product offerings.

Thiltgen holds an MBA from Vanderbilt University's Owen Graduate School of Management and a bachelor's degree in government from the University of Texas at Austin.

You May Also Be Interested In

• UWMC urges Two Harbors stockholders to reject CCM merger deal
• Genprex receives Canadian patent notice for Reqorsa combo therapy
• CACI International names former Lockheed Martin executive as COO